In a report issued on April 14, Whit Mayo from Leerink Partners reiterated a Buy rating on UnitedHealth (UNH – Research Report). The company’s shares closed last Monday at $534.08, close to its 52-week high of $553.29.
According to TipRanks.com, Mayo is a 4-star analyst with an average return of 8.9% and a 58.7% success rate. Mayo covers the Healthcare sector, focusing on stocks such as Airsculpt Technologies, Inc., Alignment Healthcare, and Privia Health Group.
UnitedHealth has an analyst consensus of Strong Buy, with a price target consensus of $579.54, a 7.7% upside from current levels. In a report released yesterday, Deutsche Bank also maintained a Buy rating on the stock with a $549.00 price target.
Based on UnitedHealth’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $79.78 billion and net profit of $5.03 billion. In comparison, last year the company earned revenue of $69.74 billion and had a net profit of $4.86 billion.
Based on the recent corporate insider activity of 158 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UNH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
UnitedHealth Group, Inc. is a diversified healthcare company, offering healthcare coverage and benefits services through UnitedHealthcare, and information and technology-enabled health services through Optum. The company was founded by Richard T. Burke in January 1977 and is headquartered in Minneapolis, MN.
Read More on UNH: